ArticleEULAR rheumatology open2026
Antirheumatic medication use among pregnant women with rheumatoid arthritis: a Norwegian nationwide drug utilisation study.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Managing rheumatoid arthritis (RA) during pregnancy requires balancing maternal health and foetal safety. This study examined the prevalence, temporal trends, utilisation patterns, and concurrent use of antirheumatic medications from preconception through the postpartum period. Methods: We conducted a nationwide study using Norwegian registry data (2006-2018), linking the medical birth registry with prescription and primary care records. Pregnant women with RA were identified through diagnostic codes. Dispensed prescriptions were evaluated from 9 months before the last menstrual period to 9 months after delivery. Multitrajectory models identified distinct patterns of antirheumatic medication use over time. Results: Of 769,524 pregnancies, 3732 (0.5%) occurred in women with RA. In the period around pregnancy, 52.9% used non-steroidal anti-inflammatory drugs (NSAIDs), 33.6% glucocorticoids, 17.7% pregnancy-compatible conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), 14.8% pregnancy-contraindicated csDMARDs, and 21.6% tumour necrosis factor (TNF) inhibitors. Medication use declined from 61.3% preconceptionally to 37.6%, 22.1%, and 18.9% in the first, second, and third trimesters, respectively, then increased to 53.0% postpartum. From 2008 to 2018, antirheumatic medication use increased preconceptionally (59.8%-65.7%), during pregnancy (30.6%-49.5%), and postpartum (45.1%-54.1%), mainly due to increased TNF inhibitor use. Three distinct medication use patterns emerged: (i) NSAID-dominant use prepregnancy, (ii) glucocorticoid plus pregnancy-compatible csDMARD use continuing into pregnancy; and (iii) pregnancy-contraindicated csDMARD interrupters, mostly discontinuing during pregnancy and restarting postpartum. Conclusions: Although antirheumatic medication use increased over time, most women discontinued treatment during pregnancy and resumed it after childbirth. The 3 distinct usage patterns highlight the need for individualised counselling and close monitoring to optimise disease management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.